Up next

Autoplay

Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders

3 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

Dr. Peter Nash discusses abstract OP0023 from EULAR 2022 -
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG https://bit.ly/3akPfWJ

Show more
0 Comments sort Sort By

Up next

Autoplay